Omnicell (NASDAQ:OMCL) Upgraded at Wall Street Zen

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently weighed in on the stock. Benchmark lowered their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Bank of America lifted their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 target price (up from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Trading Down 0.0%

Omnicell stock traded down $0.01 during mid-day trading on Friday, reaching $27.56. 280,928 shares of the company traded hands, compared to its average volume of 562,602. The firm's 50 day moving average price is $28.93 and its 200 day moving average price is $34.50. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 59.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The company had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. During the same period in the prior year, the firm posted $0.03 EPS. Omnicell's revenue for the quarter was up 9.5% on a year-over-year basis. On average, analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

A number of large investors have recently made changes to their positions in OMCL. Summit Investment Advisors Inc. raised its holdings in shares of Omnicell by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after acquiring an additional 307 shares in the last quarter. Hillsdale Investment Management Inc. raised its holdings in shares of Omnicell by 0.5% in the fourth quarter. Hillsdale Investment Management Inc. now owns 92,897 shares of the company's stock valued at $4,136,000 after acquiring an additional 420 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock valued at $50,000 after acquiring an additional 458 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Omnicell by 2.3% in the first quarter. Diversified Trust Co now owns 22,660 shares of the company's stock valued at $792,000 after acquiring an additional 513 shares in the last quarter. Finally, Bridge City Capital LLC raised its holdings in shares of Omnicell by 1.6% in the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after acquiring an additional 650 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.